Edgar Filing: HALOZYME THERAPEUTICS INC - Form 4

HALOZYMI Form 4 May 16, 200'	E THERAPEUTICS IN	ĩC				
FORM	1 /			OMB API	PROVAL	
	UNITED STAT	YES SECURITIES AND EXCHANGE Washington, D.C. 20549	COMMISSION	OMB Number:	3235-0287 January 31,	
Check thi if no long subject to Section 1 Form 4 or	6.	x STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES				
Form 4 or Form 5 obligations may continue. See Instruction 1(b). Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940						
(Print or Type R	Responses)					
1. Name and A Engler Robe	ddress of Reporting Person ert	 2. Issuer Name and Ticker or Trading Symbol HALOZYME THERAPEUTICS INC [HTI] 	5. Relationship of I Issuer (Check	Reporting Perso	on(s) to	
	(First) (Middle) ZYME JTICS, INC., 11588 DVALLEY RD., SUIT	3. Date of Earliest Transaction (Month/Day/Year) 05/15/2007 È	X Director Officer (give t below)		Owner (specify	
	(Street)	4. If Amendment, Date Original Filed(Month/Day/Year)	 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting 			
SAN DIEGO	O, CA 92121		Person	ore than One Rep	orting	
(City)	(State) (Zip)	Table I - Non-Derivative Securities Advised to the security advised t	cquired, Disposed of,	or Beneficially	Owned	
1.Title of Security (Instr. 3)	any	ution Date, if Transaction(A) or Disposed of (D) Code (Instr. 3, 4 and 5) th/Day/Year) (Instr. 8) (A) or	 Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 	Ownership Form: Direct (D) or	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Common Stock	05/15/2007	Code V Amount (D) Pric A $15,000$ A $\begin{array}{c} \$\\ 10.3\end{array}$	40.000	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Edgar Filing: HALOZYME THERAPEUTICS INC - Form 4

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. Number of orDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Options to purchase common stock.	\$ 10.37	05/15/2007		A	10,000	05/15/2007	05/15/2017	Common Stock	10,000

Reporting Owners

Reporting Owner Name / Address		Relationships				
		Director	10% Owner	Officer	Other	
Engler Robert C/O HALOZYME THERAPEUTICS, INC. 11588 SORRENTO VALLEY RD., SUITE 17 SAN DIEGO, CA 92121		Х				
Signatures						
/s/ Robert L. Engler	05/16/2007					

<u>**</u>Signature of Reporting Person

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

Date

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.